Immunohistochemical analysis in ethinylestradiol-treated breast cancers after prior long-term estrogen-deprivation therapy

SpringerPlus
Y OmotoHirotaka Iwase

Abstract

Estrogen receptor (ER) positive breast cancer can often be treated by hormone therapy; however a certain population of ER-positive patients become resistant to hormone therapy after long-term hormone treatment. Ethinylestradiol (EE2) is a derivative of estrogen, which has shown promising effects in these patients. We successfully obtained tissue samples from 6 patients undergoing EE2 treatment and examined 13 well-known breast cancer-related factors by immunohistochemistry. Of the 6 patients, 5 responded but one patient did not. Before EE2 treatment, staining for both ER and androgen receptor (AR) was strong in the nucleus, and the progesterone receptor (PgR) was almost no staining. EE2 treatment significantly down-regulated ER and up-regulated PgR while nuclear and cytosolic AR were oppositely down- and up-regulated, respectively. Cytosolic staining of BRCA1 was significantly up-regulated by EE2 whereas nuclear staining tended to decrease. Individual comparisons suggested less induction of PgR and decreasing AKT but increasing pAKT in the non-responder following EE2 treatment. Our observations revealed that EE2 activated ER downstream genes; however it did not stimulate cell growth. This suggests that hormone resistant cells m...Continue Reading

References

Jul 9, 1998·Molecular Carcinogenesis·D RomagnoloC A Afshari
Apr 8, 1999·Molecular Pathology : MP·J A DuncanT G Cooke
Sep 23, 2000·Molecular and Cellular Endocrinology·V Panet-RaymondM A Trifiro
Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·T SørlieA L Børresen-Dale
Jun 14, 2005·Molecular and Cellular Endocrinology·Sanjay KansraNira Ben-Jonathan
Aug 18, 2005·Journal of the National Cancer Institute·Lisa M McShaneUNKNOWN Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics
Sep 24, 2008·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Hirotaka Iwase
Mar 25, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Stephen R D Johnston
Apr 21, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M Elizabeth H HammondAntonio C Wolff
Jul 10, 2012·Journal of the National Comprehensive Cancer Network : JNCCN·Robert W CarlsonUNKNOWN National Comprehensive Cancer Network
Mar 5, 2013·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Toru Watanabe
Jul 17, 2013·Cancer Cell International·Natalie TulchinAlvaro Na Monteiro
Oct 1, 2013·The Breast : Official Journal of the European Society of Mastology·Rachel C JankowitzNancy E Davidson
Oct 9, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio C WolffUNKNOWN College of American Pathologists
Oct 17, 2013·The Journal of Steroid Biochemistry and Molecular Biology·Natsu FujikiShin-ichi Hayashi
Jan 9, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rinath JeselsohnVincent A Miller

❮ Previous
Next ❯

Citations

Oct 6, 2015·Translational Research : the Journal of Laboratory and Clinical Medicine·Takashi TakeshitaHirotaka Iwase

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Software Mentioned

JMP
SAS

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.